Mon. 8 Apr 2024, 2:15am ET
Benzinga
News
- Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC
- Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting characterized by shorter duration of response to osimertinib
- BDTX-1535 profile differentiated as the most advanced fourth-generation oral TKI in clinical development addressing the full spectrum of classical, non-classical, and C797S resistance EGFR mutations